FDA opens doors to biosimilar, interchangable insulin products - analysts doubt impact
On Monday, a regulatory change came into force, meaning that it will now be possible to get biosimilar insulin approved in the USA. The former head of the FDA called it a paradigm shift, but analysts doubt it will topple the insulin market.
BY KEVIN GRØNNEMANN, TRANSLATED BY CATHERINE BRETT
A simple regulatory change in the USA has made it possible to buy biosimilar insulin in the country for the first time.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75){kind=logo}
